Drools URS PetHep Hepatoprotective Liver Support Oral Suspension for Dogs & Cats | Liver Function, Detoxification, Appetite & Recovery Support | 100ml

VETERINARY SUPPLEMENT — For veterinary use only. Administer under the supervision of a licensed veterinarian. For animals with diagnosed liver disease, use only as directed by a veterinarian with appropriate clinical monitoring (liver enzymes ALT, ALP, GGT, bilirubin; hepatic ultrasound; bile acids testing). Shake well before each use. Keep out of reach of children. Store in a cool, dry place away from direct sunlight; keep bottle tightly closed after use.

Drools URS PetHep Hepatoprotective Liver Support Oral Suspension for Dogs & Cats (100ml)

Drools URS PetHep is a veterinary hepatoprotective liver support oral suspension for dogs and cats, formulated with Ursodeoxycholic Acid (UDCA — also known as Ursodiol) as the primary hepatoprotective active ingredient. UDCA is a naturally occurring secondary bile acid with well-established hepatoprotective, choleretic, immunomodulatory, and anti-apoptotic properties in veterinary medicine. URS PetHep supports healthy liver function, promotes bile flow, reduces bile acid-mediated hepatocellular toxicity, aids liver cell regeneration, and improves appetite and vitality in dogs and cats with liver stress, cholestatic liver disease, chronic hepatitis, or hepatic disorders. Confirm complete composition and UDCA concentration from the Drools URS PetHep product label before use.

Composition

• Ursodeoxycholic Acid (UDCA / Ursodiol) — confirm concentration from product label: Secondary bile acid; naturally produced in small quantities by hepatic bacterial metabolism of primary bile acids (chenodeoxycholic acid); mechanism of hepatoprotection — (1) Hydrophilic bile acid displacement: UDCA displaces cytotoxic hydrophobic bile acids (chenodeoxycholic acid, deoxycholic acid, lithocholic acid) from the circulating bile acid pool by competitive displacement; hydrophobic bile acids cause direct hepatocellular membrane damage, mitochondrial dysfunction, and hepatocyte apoptosis in cholestatic liver disease; UDCA replacement of the bile acid pool with a more hydrophilic, less cytotoxic bile acid significantly reduces hepatocellular injury in cholestatic conditions; (2) Choleretic activity: UDCA stimulates bile flow (choleresis) and promotes biliary excretion of toxic bile acid metabolites, bilirubin, and other hepatotoxic substances; improved bile flow reduces intrahepatic bile accumulation (cholestasis) and its associated hepatocellular damage; (3) Immunomodulatory activity: UDCA modulates aberrant hepatic immune responses in immune-mediated hepatitis and cholangiohepatitis; reduces MHC class I antigen expression on hepatocytes, reducing hepatocyte recognition and attack by cytotoxic T-lymphocytes; reduces pro-inflammatory cytokine production (TNF-α, IL-1) in hepatic tissue; (4) Anti-apoptotic activity: UDCA inhibits hepatocyte apoptosis (programmed cell death) by stabilising mitochondrial membranes and preventing cytochrome c release from mitochondria, which would otherwise trigger the intrinsic apoptotic cascade; reduces mitochondrial permeability transition pore (MPTP) opening; (5) Cytoprotective membrane stabilisation: UDCA incorporates into hepatocyte and cholangiocyte plasma membranes, reducing their susceptibility to detergent-like damage from hydrophobic bile acids; (6) Hepatocyte regeneration support: Reduced hepatocellular apoptosis and cytotoxicity creates a more favourable microenvironment for hepatic regeneration and recovery
• Oral suspension base (may include flavouring agents for palatability) — confirm from Drools URS PetHep product label

Therapeutic Class

• Veterinary hepatoprotective oral suspension — Ursodeoxycholic Acid (UDCA) — choleretic, immunomodulatory, anti-apoptotic, and cytoprotective liver support for dogs and cats

Indications

• Cholestasis and cholestatic liver disease — intrahepatic cholestasis in dogs and cats; UDCA is a first-line hepatoprotective agent for cholestatic conditions; reduces intrahepatic bile acid accumulation and its associated hepatocellular toxicity
• Cholangiohepatitis (inflammatory liver and bile duct disease) — particularly in cats; UDCA's immunomodulatory and choleretic properties are beneficial in feline cholangiohepatitis, one of the most common feline liver diseases
• Chronic hepatitis — adjunctive hepatoprotective and immunomodulatory therapy in dogs and cats with chronic hepatitis; reduces immune-mediated hepatocellular destruction
• Fatty liver disease (hepatic lipidosis) — particularly feline hepatic lipidosis; UDCA supports hepatocyte survival and bile flow during fatty liver recovery; adjunctive to nutritional management
• Medication-induced hepatic stress — adjunctive hepatoprotective support during or after prolonged NSAID (meloxicam, carprofen), antibiotic (doxycycline, enrofloxacin), antifungal (ketoconazole, itraconazole), or anticonvulsant (phenobarbital, potassium bromide) therapy
• Bile duct disorders — bile duct mucocele (biliary mucocele) adjunctive support; extrahepatic bile duct obstruction recovery support (confirm with veterinarian); biliary sludge
• Post-illness liver recovery — hepatic regeneration and metabolic restoration following systemic illness, sepsis, tick fever, or prolonged hospitalisation
• Daily preventive liver support — maintenance hepatoprotective supplementation for geriatric dogs and cats, animals on long-term medication, or working dogs with high hepatic metabolic demand
• Appetite and vitality support — restoration of appetite and body condition in dogs and cats with hepatic dysfunction-related anorexia and lethargy

Dosage

• Administer orally as directed by a licensed veterinarian based on species, body weight, and clinical condition
• Confirm weight-based UDCA dose from Drools URS PetHep product label — standard veterinary UDCA dosing is typically 10–15mg/kg once daily (confirm from label)
• Shake well before each use; measure dose accurately with the provided measuring device
• May be administered directly into the mouth or mixed with a small amount of food

Contraindications & Precautions

• Do not use as a substitute for veterinary diagnosis and clinical management of liver disease — baseline and monitoring liver function tests (ALT, ALP, GGT, total bilirubin, serum bile acids, albumin; hepatic ultrasound; liver biopsy if indicated) are essential for appropriate diagnosis and treatment planning
• Use with caution in animals with complete extrahepatic bile duct obstruction — UDCA is a choleretic and its use in complete biliary obstruction requires veterinary assessment; confirm with veterinarian
• Do not use in animals with known hypersensitivity to UDCA or any suspension component

Safety Information

• For veterinary use only — administer under veterinary supervision
• Generally well tolerated in dogs and cats at standard doses; mild GI side effects (loose stools, occasional vomiting) may occur at initiation in some animals — administer with food if GI sensitivity occurs
• Not for human use — keep out of reach of children
• Store in a cool, dry place away from direct sunlight; keep bottle tightly closed after use; refrigerate after opening if directed on product label